Across TCGA pan-cancer cohorts, ENTPD5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ENTPD5 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ENTPD5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ENTPD5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where ENTPD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.704	0.413	<.001	103	view →
UCEC	OS	Tertile	II,III,IV	0.507	1.000	.009	22	view →
CCRCC	DFS	Quartile	II,III,IV	0.904	0.125	.024	7	view →
LUAD	DFS	Quartile	II,III,IV	0.265	0.728	.028	3	view →
HNSC	DFS	Median	IV	0.747	0.554	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ENTPD5 tumor-vs-normal RNA expression · all ENTPD5 data types